A Study of Romiplostim N01 as the First-line Treatment for Newly Diagnosed Adult Patients With ITP
Studying Autoimmune thrombocytopenia
Last synced from ClinicalTrials.gov
Key facts
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
- Intervention
- Dexamethasone Combined with romiplostim N01(drug)
- Enrollment
- 129 enrolled
- Eligibility
- 18-75 years · All sexes
- Timeline
- 2024 – 2026
Study locations (1)
- Chinese Academy of Medical Science and Blood Disease Hospital, Tianjin, Tianjin Municipality, China
Collaborators
The Second Affiliated Hospital of Kunming Medical University · Weifang People's Hospital · Shenzhen Second People's Hospital · The Affiliated Hospital of Qingdao University · Changzhi Medical College · Affiliated Hospital of Nantong University · The First People's Hospital of Yunnan · The First Affiliated Hospital of Bengbu Medical University · Suining Central Hospital · The Second Affiliated Hospital of Dalian Medical University · North China University of Science and Technology · Guizhou Provincial People's Hospital
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06658834 on ClinicalTrials.govOther trials for Autoimmune thrombocytopenia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07559331High-Dose Dexamethasone Combined With Orelabrutinib Versus High-Dose Dexamethasone Combined With Placebo in Adult Patients With Newly Diagnosed Primary Immune ThrombocytopeniaShandong University
- RECRUITINGPHASE2NCT07362238Daratumumab Versus Rituximab in the Management of Pediatric Primary Immune Thrombocytopenia (ITP)Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT07362199Anti-CD38 Monoclonal Antibody Combined With Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGEARLY PHASE1NCT07441525UCAR-T Targeting CD19/BCMA in Subjects With Autoantibody-Mediated Autoimmune Benign Hematological DiseasesUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology
- RECRUITINGPHASE2NCT07234019Rituximab Combining Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT07297563Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT07294365A Study of DZD8586 in Adults With Primary Immune Thrombocytopenia (ITP) (TAI-SHAN11)Dizal Pharmaceuticals
- RECRUITINGPHASE2NCT07104565Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell DisordersIncyte Corporation